ENACT: The efficacy and mechanisms of action of N-acetylcysteine as an adjunct treatment for first episode psychosis.

Dataset derived from a 52-week randomized, double-blind, placebo-controlled trial investigating the efficacy of N-acetyl cysteine (NAC) as an adjunctive treatment for young individuals experiencing first episode psychosis (FEP). The study aims to determine if NAC, administered at 2000 mg daily in addition to treatment as usual (TAU), can reduce symptom severity and prevent the progression of early psychosis into a chronic disorder. The trial involves 162 participants aged 15-25 years, recruited from the Early Psychosis Prevention and Intervention Centre, who are randomized to receive either NAC or placebo for 26 weeks, followed by a 26-week non-treatment follow-up period.